Correlation of MSH3 polymorphisms with response and survival in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy

Genetics and Molecular Research

Volumn 14, Issue 2, 2015, Pages 3525-3533

  Xu, X L ^a   Yao, Y L ^a   Xu, W Z ^a   Feng, J G ^a   Mao, W M ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

MutS homolog 3; Non small cell lung cancer; Platinum based chemotherapy; Single nucleotide polymorphism

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM COMPLEX; PROTEIN MSH3; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; MSH3 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC CORRELATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MISMATCH REPAIR; MSH3 GENE; NON SMALL CELL LUNG CANCER; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LINKAGE DISEQUILIBRIUM; LUNG NEOPLASMS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84945947619     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.April.15.16     Document Type: Article

References (18)

1. Conde J, Silva SN, Azevedo AP, Teixeira V, et al. (2009). Association of common variants in mismatch repair genes and breast cancer susceptibility: a multigene study. BMC Cancer 9: 344.
2. Conde-Pérezprina JC, Léon-Galván MÁ and Konigsberg M (2012). DNA mismatch repair system: repercussions in cellular homeostasis and relationship with aging. Oxid. Med. Cell. Longev. 2012:728430.
3. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, et al. (2012). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11.
4. Gurubhagavatula S, Liu G, Park S, Zhou W, et al. (2004). XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol. 22: 2594-2601.
5. Harrington JM and Kolodner RD (2007). Saccharomyces cerevisiae Msh2-Msh3 acts in repair of base-base mispairs. Mol. Cell. Biol. 27: 6546-6554.
6. Hirata H, Hinoda Y, Kawamoto K, Kikuno N, et al. (2008). Mismatch repair gene MSH3 polymorphism is associated with the risk of sporadic prostate cancer. J. Urol. 179: 2020-2024.
7. Kelsey CR, Jackson IL, Langdon S, Owzar K, et al. (2013). Analysis of single nucleotide polymorphisms and radiation sensitivity of the lung assessed with an objective radiologic endpoin. Clin. Lung Cancer 14: 267-274.
8. Kothandapani A, Sawant A, Dangeti VS, Sobol RW, et al. (2013). Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity. Nucleic Acids Res. 41: 7332-7343.
9. Li GM (2008). Mechanisms and functions of DNA mismatch pair. Cell Res. 18: 85-98.
10. Mondal P, Datta S, Maiti GP, Baral A, et al. (2013). Comprehensive SNP scan of DNA repair and DNA damage response genes reveal multiple susceptibility loci conferring risk to tobacco associated leukoplakia and oral cancer. PLoS One 8: e56952.
11. Park JM, Huang S, Tougeron D and Sinicrope FA (2013). MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells. PLoS One 8: e65369.
12. Song H, Ramus SJ, Quaye L, DiCioccio RA, et al. (2006). Common variants in mismatch repair genes and risk of invasive ovarian cancer. Carcinogenesis 27: 2235-2242.
13. Takahashi M, Koi M, Balaguer F, Boland CR, et al. (2011). MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. J. Biol. Chem. 286: 12157-12165.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92: 205-216.
15. Vogelsang M, Wang Y, Veber N, Mwapagha LM, et al. (2012). The cumulative effects of polymorphisms in the DNA mismatch repair genes and tobacco smoking in oesophageal cancer risk. PLoS One 7: e36962.
16. Wei SZ, Zhan P, Shi MQ, Shi Y, et al. (2011). Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med. Oncol. 28: 315-321.
17. Xie FJ, Zhao P, Kou JY, Hong W, et al. (2012). The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum. Cancer Chemother. Pharmacol. 69: 1443-1448.
18. Zhu G and Lippard SJ (2009). Photoaffinity labeling reveals nuclear proteins that uniquely recognize cisplatin-DNA interstrand cross-links. Biochemistry 48: 4916-4925.